

DEVICE FOR AUTOMATIC GLUCOSE MONITORING AND CONTROLLED INSULIN DOSAGE

Device that helps improve the quality of life of patients with Type I Diabetes (Juvenile Diabetes).



BACKGROUND

Worldwide, more than 300 million people have been diagnosed with diabetes (of which 10% of cases are Type I, or Juvenile Diabetes), and another 180 million live with undiagnosed diabetes.

The supply of drugs to the human body, such as insulin, has generated new alternatives, but controlled and continuous dosing remains a challenge

TECHNOLOGY

This device is designed primarily for patients with Type I Diabetes, as it is an automated glucose device that has the option to be manually controlled through microneedles and microfluidic channels. It includes a module that does the blood sampling and sends it to a controller, then the microneedles release insulin to the body, and a user interface allows entering the patient's information.

KEY BENEFITS

- An automated device that has the option to be manually controlled.
- Insulin is released evenly in the body (subcutaneous).
- Continuous monitoring of blood glucose.
- The device compares results from blood samples and automatically supplies the required insulin to the user.

DEVELOPMENT STATUS

- Prototype Design.
Technology Readiness Level: 3/9

INTELLECTUAL PROPERTY

Granted Patent: MX 338466

This technology is available for licensing. More opportunities on our website: <http://redottec.com>



Tecnológico de Monterrey

Av. Eugenio Garza Sada No.427, Col. Altavista Monterrey, Nuevo León, México. C.P. 648449

(81)8358-2000 Ext. 5626

ott.mty@itesm.mx

OTT - Oficina de Transferencia de Tecnología del Tecnológico de Monterrey

OTT ITESM MTY

OTT Tecnológico de Monterrey